Shares of Hims & Hers Health (NYSE:HIMS) stock are skyrocketing higher by over 25% after the telehealth company announced that it would provide access to GLP-1 weight-loss injections.Hims & Hers has partnered with an undisclosed manufacturer of generic and 503B compounded injectable medications to provide the injections. The process of compounded drugs occurs when pharmacies make copies of a drug experiencing a shortage and is allowed in the U.S. Compounded drugs are also less scrutinized by the Food and Dr ...